Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist

References

• Cenksoy C, Cenksoy PO, Erdem O, et al. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model. Eur J Obstet Gynecol Reprod Biol 2014;174:86–90
   PubMed Web of Science ®Google Scholar
• Aboulghar MA, Mansour RT, Serour GI, et al. Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 1999;87:81–5
   PubMed Web of Science ®Google Scholar
• Aboulghar MA, Mansour RT, Serour GI, et al. Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol 1993;81:108–11
   PubMed Web of Science ®Google Scholar
• Ozcakir HT, Giray SG, Ozbilgin MK, et al. Effect of angiotensin-converting enzyme-inhibiting therapy on the expression of vascular endothelial growth factor in hyperstimulated rat ovary. Fertil Steril 2004;82:1127–32
   PubMed Web of Science ®Google Scholar
• Neulen J, Yan Z, Raczek S, et al. Human chorionic gonadotropin–dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995;80:1967–71
   PubMed Web of Science ®Google Scholar
• Gomez R, Simon C, Remohi J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 2003;68:2164–71
   PubMed Web of Science ®Google Scholar
• Pellicer A, Albert C, Mercader A, et al. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999;71:482–9
   PubMed Web of Science ®Google Scholar
• Cohen T, Nahari D, Cerem LW, Neufeld G. Interleukin induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736–41
   PubMed Web of Science ®Google Scholar
• Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010;94:389–400
   PubMed Web of Science ®Google Scholar
• Friedlander MA, Loret de Mola JR, Goldfarb JM. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril 1993;60:826–33
   PubMed Web of Science ®Google Scholar
• Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997;3:255–66
   PubMed Web of Science ®Google Scholar
• Navarro-Millán I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 2012;34:788–802
   PubMed Web of Science ®Google Scholar
• Artini PG, Monti M, Fasciani A, et al. Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 2002;101:169–74
   PubMed Web of Science ®Google Scholar
• Loret de Mola JR, Flores JP, Baumgardner GP, et al. Elevated interleukin-6 levels in the ovarian hyperstimulation syndrome: ovarian immunohistochemical localization of interleukin-6 signal. Obstet Gynecol 1996;87:581–7
   PubMed Web of Science ®Google Scholar
• Wei LH, Chou CH, Chen MW, et al. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model. J Clin Endocrinol Metab 2014;98:E472–84
   Google Scholar
• Gómez R, Soares SR, Busso C, et al. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med 2010;28: 448–57
   PubMed Web of Science ®Google Scholar
• Engin-Ustun Y, Yılmaz S, Timur H, et al. Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model. Gynecol Endocrinol 2013;29:851–4
   PubMed Web of Science ®Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400–11
   PubMed Web of Science ®Google Scholar
• Busso CE, Garcia-Velasco J, Gomez R, et al. Symposium: update on prediction and management of OHSS. Prevention of OHSS–dopamine agonists. Reprod Biomed Online 2009;19:43–51
   PubMed Web of Science ®Google Scholar
• Saylan A, Arioz DT, Koken T, et al. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand 2010;89:692–9
   PubMed Web of Science ®Google Scholar
• Hill MJ, Chason RJ, Payson MD, et al. GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes. Reprod BioMed Online 2012;25:284–91
   PubMed Web of Science ®Google Scholar
• Tong XM, Zhang SY, Song T, et al. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. Chin Med J (Engl) 2008;121:2434–9
   PubMed Web of Science ®Google Scholar
• Sari ES, Yazıcı A, Aksit H, et al. Inhibitory effect of sub-conjunctival tocilizumab on alkali burn induced corneal neovascularization in rats. Curr Eye Res 2015;40:48–55
   PubMed Web of Science ®Google Scholar